# AIM Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aim-biotech

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.aimbiotech.com
- Total disclosed funding: $4.6M
- Latest round: Seed (Feb 2, 2021)
- Investors on record: 5

## About

Based in Singapore, and founded in 2012 by Kuan Chee Mun, AIM Biotech, aka AIM Biotech Pte. Ltd., operates as a biotechnology firm that delivers the idenTx humanized BioAvatar platform, which aids in the drug discovery process and gives pre-clinical insights to design and manufacture targeted therapies solutions. As of 2022, the firm is led by its CEO Jim McGorry.

AIM Biotech platform includes idenTx which allows the creation of 3D microphysiological structures for research studies, medicinal chemistry and production, and customized therapeutic formulation. The firm’s solutions are applicable for immune cell-mediated killing, immunotherapy checkpoint modulation, extravasation, cell invasion, vasculogenesis, angiogenesis, spheroid dispersion, blood-brain barrier model, and others.

## Funding rounds

- Seed, Feb 2, 2021, $4.6M — Wavemaker Partners, VentureCraft, SEEDS Capital, elev8.vc, Black Kite Capital

## Investors

- Wavemaker Partners (https://capitalatlas.ai/funds/wavemaker-partners) — Seed
- VentureCraft (https://capitalatlas.ai/funds/venturecraft) — Seed
- SEEDS Capital (https://capitalatlas.ai/funds/seeds-capital) — Seed
- elev8.vc (https://capitalatlas.ai/funds/elev8-vc) — Seed
- Black Kite Capital (https://capitalatlas.ai/funds/black-kite-capital) — Seed